Medical marijuana laws and driving under the influence of marijuana and alcohol.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
10 2020
Historique:
received: 01 07 2019
revised: 14 10 2019
accepted: 03 03 2020
pubmed: 7 3 2020
medline: 20 4 2021
entrez: 7 3 2020
Statut: ppublish

Résumé

Medical marijuana law (MML) enactment in the United States has been associated with increased cannabis use but lower traffic fatality rates. We assessed the possible association of MML and individual-level driving under the influence of cannabis (DUIC) and also under the influence of alcohol (DUIA). Three cross-sectional U.S. adult surveys: The National Longitudinal Alcohol Epidemiologic Survey (NLAES; 1991-1992), the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC; 2001-2002), and the NESARC-III (2012-2013). The total n was 118 497: 41 764, 41 184, and 35 549 from NLAES, NESARC, and NESARC-III, respectively. Across the three surveys, similar questions in the Alcohol Use Disorder and Associated Disabilities Interview Schedule assessed DUIC and DUIA. Ever-MML states enacted MML between 1991-1992 and 2012-2013 (overall period). Early-MML states enacted MML between 1991-1992 and 2001-2002 (early period). Late-MML states enacted MML between 2001-2002 and 2012-2013 (late period). MML effects on change in DUIC and DUIA prevalence were estimated using a difference-in-differences specification to compare changes in MML and other states. From 1991-1992 to 2012-2013, DUIC prevalence nearly doubled (from 1.02% to 1.92%), increasing more in states that enacted MML than other states (difference-in-differences [DiD] = 0.59%; 95% CI = 0.06%-1.12%). Most change in DUIC prevalence occurred between 2001-2002 and 2012-2013. DUIC prevalence increased more in states that enacted MML 2001-2002 to 2012-2013 than in never-MML states (DiD = 0.77%; 95% CI = -0.05%-1.59%), and in two early-MML states, California (DiD = 0.82; 95% CI = 0.06-1.59) and Colorado (DiD = 1.32; 95% CI = 0.11-2.53). In contrast, DUIA prevalence appeared unrelated to MML enactment. Medical marijuana law enactment in US states appears to have been associated with increased prevalence of driving under the influence of cannabis, but not alcohol.

Identifiants

pubmed: 32141142
doi: 10.1111/add.15031
pmc: PMC7483706
mid: NIHMS1573784
doi:

Substances chimiques

Medical Marijuana 0
Ethanol 3K9958V90M

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1944-1953

Subventions

Organisme : NIDA NIH HHS
ID : R01 DA048860
Pays : United States
Organisme : NIDA NIH HHS
ID : T32 DA031099
Pays : United States
Organisme : NIMH NIH HHS
ID : T32 MH017119
Pays : United States

Informations de copyright

© 2020 Society for the Study of Addiction.

Références

J Anal Toxicol. 2014 Oct;38(8):569-74
pubmed: 25217548
JAMA Psychiatry. 2017 Nov 1;74(11):1095-1103
pubmed: 28903161
Addict Behav. 2005 Mar;30(3):619-26
pubmed: 15718082
Lancet Psychiatry. 2015 Jul;2(7):601-8
pubmed: 26303557
Drug Alcohol Depend. 2004 Jun 11;74(3):223-34
pubmed: 15194200
Accid Anal Prev. 1994 Feb;26(1):63-78
pubmed: 8110358
J Drug Policy Anal. 2014 Dec;7(1):1-19
pubmed: 25657828
Drug Alcohol Depend. 2016 Dec 01;169:26-32
pubmed: 27755989
Arch Gen Psychiatry. 2004 Apr;61(4):361-8
pubmed: 15066894
J Stud Alcohol Drugs. 2010 Jul;71(4):480-7
pubmed: 20553656
Alcohol Health Res World. 1994;18(3):243-248
pubmed: 31798130
Health Serv Res. 2009 Feb;44(1):288-302
pubmed: 18793213
Am J Epidemiol. 2014 Mar 15;179(6):692-9
pubmed: 24477748
J Drug Issues. 2017 Jan;47(1):74-90
pubmed: 28458396
Addiction. 2012 Oct;107(10):1837-44
pubmed: 22553980
Subst Abus. 2018 Jan 2;39(1):21-26
pubmed: 28799883
J Anal Toxicol. 2005 Jul-Aug;29(5):327-38
pubmed: 16105257
Inj Epidemiol. 2014 Dec;1(1):26
pubmed: 27747660
Drug Alcohol Depend. 2012 Jan 1;120(1-3):22-7
pubmed: 22099393
J Health Econ. 2015 Jul;42:64-80
pubmed: 25863001
Arch Gen Psychiatry. 2004 Aug;61(8):807-16
pubmed: 15289279
Drug Alcohol Depend. 2015 Sep 1;154:25-37
pubmed: 26144593
Am J Public Health. 2017 Feb;107(2):336-342
pubmed: 27997245
Lancet Psychiatry. 2016 Oct;3(10):954-964
pubmed: 27592339
BMJ. 2013 Jul 31;347:f4755
pubmed: 23903247
J Drug Educ. 2006;36(4):335-55
pubmed: 17533805
Addiction. 2019 May;114(5):847-856
pubmed: 30719794
Lancet Oncol. 2012 May;13(5):450
pubmed: 22701888
J Anal Toxicol. 2005 Nov-Dec;29(8):842-3
pubmed: 16356342
N Engl J Med. 2017 Feb 23;376(8):705-707
pubmed: 28225673
Drug Alcohol Rev. 2018 Jul;37(5):637-644
pubmed: 29464852
JAMA Pediatr. 2017 Feb 1;171(2):142-149
pubmed: 28027345
J Policy Anal Manage. 2014 Winter;33(1):221-32
pubmed: 24358533
Ann Emerg Med. 2015 Dec;66(6):669
pubmed: 26918254
Arch Gen Psychiatry. 2002 Sep;59(9):794-800
pubmed: 12215078
Mol Interv. 2005 Feb;5(1):20-8
pubmed: 15731502
J Health Econ. 2012 Jan;31(1):112-21
pubmed: 22381404
J Anal Toxicol. 2009 Oct;33(8):469-77
pubmed: 19874654
Drug Alcohol Rev. 2004 Sep;23(3):319-44
pubmed: 15370012
JAMA Psychiatry. 2017 May 1;74(5):445-455
pubmed: 28355458
JAMA Psychiatry. 2017 Jun 1;74(6):579-588
pubmed: 28445557
MMWR Surveill Summ. 2016 Sep 02;65(11):1-28
pubmed: 27584586
Drug Alcohol Depend. 2014 Oct 1;143:244-50
pubmed: 25156224
JAMA. 2018 Apr 10;319(14):1444-1472
pubmed: 29634829
J Clin Psychiatry. 1999 Jun;60(6):395-9
pubmed: 10401919
Am J Community Psychol. 2013 Mar;51(1-2):278-88
pubmed: 22821130
JAMA Psychiatry. 2017 Sep 1;74(9):911-923
pubmed: 28793133
PLoS One. 2016 Jan 22;11(1):e0146853
pubmed: 26800209
JAMA. 2004 May 5;291(17):2114-21
pubmed: 15126440
Addiction. 2016 Dec;111(12):2187-2195
pubmed: 27393902
JAMA Psychiatry. 2015 Dec;72(12):1235-42
pubmed: 26502112
JAMA Psychiatry. 2015 Aug;72(8):757-66
pubmed: 26039070

Auteurs

David S Fink (DS)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Malki Stohl (M)

New York State Psychiatric Institute, New York, NY, USA.

Aaron L Sarvet (AL)

Department of Epidemiology, T.H. Chan School of Public Health, Harvard, Boston, MA, USA.

Magdalena Cerda (M)

Department of Population Health, New York University, New York, NY, USA.

Katherine M Keyes (KM)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.

Deborah S Hasin (DS)

Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
New York State Psychiatric Institute, New York, NY, USA.
Department of Psychiatry, College of Physicians and Surgeons, Columbia University, New York, NY, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH